Bis Regina L, Mallela Krishna M G
Department of Pharmaceutical Sciences & Center for Pharmaceutical Biotechnology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, C238, Aurora, CO 80045, United States.
Department of Pharmaceutical Sciences & Center for Pharmaceutical Biotechnology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, C238, Aurora, CO 80045, United States.
Int J Pharm. 2014 Sep 10;472(1-2):356-61. doi: 10.1016/j.ijpharm.2014.06.044. Epub 2014 Jun 27.
Antimicrobial preservatives (APs) are included in liquid multi-dose protein formulations to combat the growth of microbes and bacteria. These compounds have been shown to cause protein aggregation, which leads to serious immunogenic and toxic side-effects in patients. Our earlier work on a model protein cytochrome c (Cyt c) demonstrated that APs cause protein aggregation in a specific manner. The aim of this study is to validate the conclusions obtained from our model protein studies on a pharmaceutical protein. Interferon α-2a (IFNA2) is available as a therapeutic treatment for numerous immune-compromised disorders including leukemia and hepatitis C, and APs have been used in its multi-dose formulation. Similar to Cyt c, APs induced IFNA2 aggregation, demonstrated by the loss of soluble monomer and increase in solution turbidity. The extent of IFNA2 aggregation increased with the increase in AP concentration. IFNA2 aggregation also depended on the nature of AP, and followed the order m-cresol>phenol>benzyl alcohol>phenoxyethanol. This specific order exactly matched with that observed for the model protein Cyt c. These and previously published results on antibodies and other recombinant proteins suggest that the general mechanism by which APs induce protein aggregation may be independent of the protein.
抗菌防腐剂(APs)被添加到液体多剂量蛋白质制剂中以抑制微生物和细菌的生长。这些化合物已被证明会导致蛋白质聚集,从而在患者中引发严重的免疫原性和毒性副作用。我们早期对模型蛋白细胞色素c(Cyt c)的研究表明,APs以特定方式导致蛋白质聚集。本研究的目的是验证从我们对模型蛋白的研究中得出的结论在药用蛋白质上是否成立。干扰素α-2a(IFNA2)可用于治疗多种免疫功能低下的疾病,包括白血病和丙型肝炎,并且APs已被用于其多剂量制剂中。与Cyt c类似,APs诱导IFNA2聚集,表现为可溶性单体的损失和溶液浊度的增加。IFNA2聚集的程度随着AP浓度的增加而增加。IFNA2聚集还取决于AP的性质,顺序为间甲酚>苯酚>苯甲醇>苯氧乙醇。这个特定顺序与模型蛋白Cyt c观察到的顺序完全一致。这些以及之前发表的关于抗体和其他重组蛋白的结果表明,APs诱导蛋白质聚集的一般机制可能与蛋白质无关。